Efficacy of the inducing chemotherapy combined with synchronized chemotherapy and radiotherapy on the local advanced cervical cancer

To explore the efficacy of inducing chemotherapy in combination with the synchronized chemotherapy and radiotherapy on the local advanced cervical cancer.

In this prospective cohort study, 212 patients with moderate or advanced cervical cancer who underwent their chemoradiotherapy were assessed. These patients were divided into the Group A, B and Group C. At 3 months, 1, 3, and 5 years after radiotherapy, efficacy and adverse effects evaluation were conducted. Data were analyzed using SPSS software.

Among Group A, B, and C, comparison over their short-term efficacy showed that the differences had no statistical significance (P > 0.05). The overall survival of patients in the Group A, B, and C was 90.12%, 85.29%, and 91.75% in the 1st year, 85.19%, 79.41%, and 88.66% in the 3rd year, and 82.72%, 73.53% and 84.54% in the 5th year; differences among these OS showed no statistical significance (P > 0.05). While the dose modification factor (DMF) rate in Group C was higher than those in Group A and B (P < 0.05), showing its radioprotective effect. The incidence of the blood responses at Grade 3 or 4 in Group A was significantly lower than those in Group B and C (P < 0.05).

Our results showed a radioprotective effect of inducing chemotherapy in combination with the synchronized chemotherapy and radiotherapy, while the possibility of risk of blood responses was relatively high. So further studies assessing blood reactions are recommended in the long term.